Overview
- Product nameAnti-RUNX2 antibodySee all RUNX2 primary antibodies ...
- DescriptionRabbit polyclonal to RUNX2
- Tested applicationsWB more details
- Species reactivityReacts with: Rat, Human
Predicted to work with: Mouse - Immunogen
Synthetic peptide: RLSDLGRIPHPSMR, corresponding to internal sequence amino acids 244-258 of Human RUNX2
Properties
- FormLiquid
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPreservative: 0.02% Sodium Azide, 0.01% Thimerosal (merthiolate)
Constituents: 2.5% BSA, 0.45% Sodium chloride, 0.1% Dibasic monohydrogen sodium phosphate -
Concentration information loading... - PurityImmunogen affinity purified
- Clonality Polyclonal
- IsotypeIgG
- Research Areas
Applications
Our Abpromise guarantee covers the use of ab81357 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Notes |
|---|---|
| WB | WB: Use a concentration of 1 µg/ml. Detects a band of approximately 56 kDa (predicted molecular weight: 56 kDa). |
Target
- FunctionTranscription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters (By similarity). Inhibits MYST4-dependent transcriptional activation.
- Tissue specificitySpecifically expressed in osteoblasts.
- Involvement in diseaseDefects in RUNX2 are the cause of cleidocranial dysplasia (CLCD) [MIM:119600]; also known as cleidocranial dysostosis (CCD). CLCD is an autosomal dominant skeletal disorder with high penetrance and variable expressivity. It is due to defective endochondral and intramembranous bone formation. Typical features include hypoplasia/aplasia of clavicles, patent fontanelles, wormian bones (additional cranial plates caused by abnormal ossification of the calvaria), supernumerary teeth, short stature, and other skeletal changes. In some cases defects in RUNX2 are exclusively associated with dental anomalies.
- Sequence similaritiesContains 1 Runt domain.
- DomainA proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes and contains the phosphorylation sites.
- Post-translational
modificationsPhosphorylated; probably by MAP kinases (MAPK) (By similarity). Isoform 3 is phosphorylated on Ser-340. - Cellular localizationNucleus.
-
Database links
- Entrez Gene: 860 Human
- Entrez Gene: 12393 Mouse
- Entrez Gene: 367218 Rat
- Omim: 600211 Human
- SwissProt: Q13950 Human
- SwissProt: Q08775 Mouse
- SwissProt: Q9Z2J9 Rat
- Unigene: 535845 Human
- Unigene: 391013 Mouse
- Unigene: 391017 Mouse
- Unigene: 214214 Rat
- Unigene: 83672 Rat
see all
Target information above from: UniProt accession
Q13950
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010)
.
-
Alternative names
- Acute myeloid leukemia 3 protein antibodyAlpha subunit 1 antibodyAML3 antibody
- CBF alpha 1 antibodyCBF-alpha-1 antibodyCBFA1 antibodyCCD antibodyCCD1 antibodyCleidocranial dysplasia 1 antibodyCore binding factor antibodyCore binding factor runt domain alpha subunit 1 antibodyCore binding factor subunit alpha 1 antibodyCore-binding factor subunit alpha-1 antibodyMGC120022 antibodyMGC120023 antibodyOncogene AML 3 antibodyOncogene AML-3 antibodyOSF 2 antibodyOSF-2 antibodyOSF2 antibodyOsteoblast specific transcription factor 2 antibodyOsteoblast-specific transcription factor 2 antibodyOTTHUMP00000016533 antibodyPEA2 alpha A antibodyPEA2-alpha A antibodyPEA2aA antibodyPEBP2 alpha A antibodyPEBP2-alpha A antibodyPEBP2A1 antibodyPEBP2A2 antibodyPEBP2aA antibodyPEBP2aA antibodyPEBP2aA1 antibodyPolyomavirus enhancer binding protein 2 alpha A subunit antibodyPolyomavirus enhancer-binding protein 2 alpha A subunit antibodyRunt domain antibodyRunt related transcription factor 2 antibodyRunt-related transcription factor 2 antibodyRUNX2 antibodyRUNX2_HUMAN antibodySL3 3 enhancer factor 1 alpha A subunit antibodySL3-3 enhancer factor 1 alpha A subunit antibodySL3/AKV core binding factor alpha A subunit antibodySL3/AKV core-binding factor alpha A subunit antibody
see all
Anti-RUNX2 antibody images
-
All lanes : Anti-RUNX2 antibody (ab81357) at 1 µg/ml
Lane 1 : Tissue lysates prepared from Rat thymus tissue.
Lane 2 : Tissue lysates prepared from Rat testicular tissue.
Lysates/proteins at 50 µg per lane.
Secondary
HRP-conjugated Goat anti-rabbit IgG at 1/3000 dilution
Predicted band size : 56 kDa -
All lanes : Anti-RUNX2 antibody (ab81357) at 1 µg/ml
Lane 1 : PC12 (Rat adrenal pheochromocytoma cell line) Whole Cell Lysate
Lane 2 : Saos 2 (Human epithelial-like osteosarcoma cell line) Whole Cell Lysate
Lane 3 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate
Lane 4 : U2OS (Human osteosarcoma cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Secondary
Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (HRP), pre-adsorbed at 1/5000 dilution
developed using the ECL technique
Performed under reducing conditions.
Predicted band size : 56 kDa
Observed band size : 56 kDa
Additional bands at : 37 kDa. We are unsure as to the identity of these extra bands.
Exposure time : 8 minutes
References for Anti-RUNX2 antibody (ab81357)
ab81357 has not yet been referenced specifically in any publications.



